| Trial ID: | L3647 |
| Source ID: | NCT00336310
|
| Associated Drug: |
Repaglinide
|
| Title: |
A Double-Blind, Randomized, Parallel, Comparative Study to Evaluate the Efficacy and Safety of an Antidiabetic Agent Repaglinide for the Treatment of Type 2 Diabetes Mellitus Patients
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Repaglinide
|
| Outcome Measures: |
Primary: change of HbA1c at 12 weeks|Change of fasting plasma glucose (FPG) at 12 weeks|Change of postprandial plasma glucose (PPG) at 12 weeks | Secondary: Safety parameters including adverse events such as hypoglycemia|change of liver and renal function test
|
| Sponsor/Collaborators: |
Sponsor: National Cheng-Kung University Hospital
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
50
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT
|
| Start Date: |
2006-07
|
| Completion Date: |
|
| Results First Posted: |
|
| Last Update Posted: |
2006-06-13
|
| Locations: |
National Cheng-Kung University Hospital, Tainan, 704, Taiwan|National Cheng-Kung University Hospital, Tainan, 704, Taiwan
|
| URL: |
https://clinicaltrials.gov/show/NCT00336310
|
